← Back to all signals
RESEARCH PAPER ANALYSIS

Educational and regional differences in population-based incidence and survival of primary central nervous system lymphoma in Finland.

AI interpretation is pending for this paper.

Open original publication →
PMID41545969
JournalBMC cancer
Publication Date2026-01-17
Ingested2026-08-02 12:06 AM
EXECUTIVE SUMMARY

What the AI sees

Not AI summarized yet.

WHY IT MATTERS

Research significance

Pending deeper interpretation.

ABSTRACT

Source abstract

BACKGROUND: This is the first nationwide population-based study to assess educational and regional differences in the incidence and survival of primary central nervous system lymphoma (PCNSL) in Finland. METHODS: Data were extracted from the Finnish Cancer Registry based on the histological diagnosis and tumor location for cases of large B-cell lymphoma (LBCL) between 2007 and 2022. Data were divided into five healthcare regions of the Finnish healthcare system, which included 623 PCNSL patients (48% female), 27% of whom had higher education, 34% had secondary education, and 39% had primary or unknown education. The incidence rates of PCNSL and LBCL were calculated and the proportion of PCNSL incidence to LBCL incidence was estimated. The age-standardized relative survival rates were calculated within subgroups defined by educational level and healthcare region. RESULTS: The annual proportion of PCNSL incidence to LBCL incidence remained stable at 6.5% between periods 2007–2014 and 2015–2022 in Finland (p = 0.324). The age-adjusted incidence rate standardized by the World Health Organization World Standard Population (WHO WSP 2000–2025) was 0.54/100,000 person-years. The incidence rates did not differ between healthcare regions (p = 0.097) or between groups defined by educational level (p = 0.725). From 2007 to 2022, the 2-year and 5-year age-adjusted relative survival rates were 38% and 30%, respectively. In between healthcare regions, the 2-year age-adjusted relative survival rate varied between 25% and 56%, and the 5-year age-adjusted relative survival rate between 16% and 45% (p < 0.001). No statistically significant difference in survival rates was observed according to the educational level (p = 0.282). CONCLUSIONS: The incidence of PCNSL in Finland remains one of the highest observed in population-based studies. However, the proportion of PCNSL incidence to LBCL incidence remained stable between periods 2007–2014 and 2015–2022. The incidence rates did not differ between educational levels or healthcare regions. A minor trend towards improved survival was observed among those with a higher educational level. Remarkable differences were observed in survival after diagnosis of PCNSL according to patients’ healthcare regions.

SUPPORTING PAPER SET

32 more papers to review

Ranked by current scoring engine
1 Effects of nutritional intervention on insulin resistance-associated inflammatory biomarkers and gene polymorphisms in gestational diabetes mellitus. Journal of medical biochemistry 67.45 2 Factors influencing health-related quality of life in children with leukemia in Saudi Arabia: a cross- sectional study. BMC pediatrics 63.8 3 Breast Cancer Patients' Parenting Concerns User Personas: A Qualitative Analysis. Current oncology (Toronto, Ont.) 57.4 4 Molecular Pathogenesis, Tumor Microenvironment and Health Disparities in Select Pediatric Solid Tumors: An Integrative Narrative Review. Diseases (Basel, Switzerland) 65.5 5 Expression VIII: Final Results of the Individual Perception and Level of Information of Patients with Borderline Tumors of the Ovary. Current oncology (Toronto, Ont.) 67.8 6 Adolescents and young adults with cancer in Switzerland: a large retrospective single-centre cohort analysis of key care pathways and outcomes by sex and age. Swiss medical weekly 79.6 7 Cellular and Immunotherapy for Pediatric Brain Tumors: A Primer. Current oncology (Toronto, Ont.) 62.52 8 Exercise and Childhood Cancer: From Science to Life "The 3rd Pediatric Exercise Oncology Congress Meets FORTEe". Current oncology (Toronto, Ont.) 66.9 9 Mitochondrial Genomic Alterations in Pediatric Acute Lymphoblastic Leukemia: Implications for Methotrexate-Induced Neurotoxicity and Ethnic Disparities. Cancer medicine 58.62 10 Two-Decade Trends in Radiotherapy Patterns and Clinical Outcomes for Soft Tissue Sarcoma: A Nationwide Study in South Korea (2005-2023). Cancer medicine 72.64 11 Re-resection at first recurrence is associated with prolonged survival in young patients with high-grade glioma: A multi-center study. Neuro-oncology advances 71.92 12 Risk Modulation by Electronic Cigarette Consumption in Cardiovascular Disease and Its Relevance in Cardiac Surgery-A Narrative Review. Journal of cardiovascular development and disease 55.0 13 Management of ectopic Cushing syndrome in medullary thyroid carcinoma: from case reports to systematic literature review. Frontiers in endocrinology 86.1 14 Comparative efficacy and safety of pharmacologic, laser, and combination therapies for infantile hemangioma: a systematic review and network meta-analysis with evidence certainty assessment. Frontiers in pharmacology 82.8 15 A PDGFRB-CD44-MIF crosstalk promotes cancer-associated cellular phenotypes in ATRT-TYR/MYC cell lines. Frontiers in oncology 51.6 16 Case Report: Two cases of secondary malignant neoplasms following treatment in pediatric patients. Frontiers in pediatrics 61.14 17 Guanfacine and HCN channels: bridging neuroinflammation and prefrontal cortex function in autism spectrum disorder. Frontiers in molecular neuroscience 62.9 18 Clinical Outcomes and New Treatments in Pediatric Brain Tumors. Current oncology (Toronto, Ont.) 52.74 19 Quality of Life in Ukrainian Children and Adolescents with Cancer Relocated to Switzerland During the Russian-Ukrainian War: An Exploratory Multicenter Study. Current oncology (Toronto, Ont.) 59.9 20 Vitamin D and Gastric Cancer: A Systematic Review and Meta-Analysis. Medical sciences (Basel, Switzerland) 73.0 21 "If I want to tap into a cord blood bank later, I felt that I should do my part and donate": Mutualism in women's accounts of umbilical cord blood donation. Social science & medicine (1982) 56.0 22 Metabolic profiling of CAR T-cells in patients reveals a shift toward amino acid-supported OXPHOS and informs transporter engineering. Research square 58.8 23 Oncohistone inhibition reshapes tumor-microenvironment communication in Diffuse Midline Glioma (DMG). bioRxiv : the preprint server for biology 58.8 24 Prenatally Detected Neonatal Neuroblastoma Associated with Achondroplasia and an SDHA Variant. Neurology international 62.8 25 Preclinical evaluation of ixazomib for high-risk pediatric brain tumors. bioRxiv : the preprint server for biology 59.7 26 Fusion Oncoprotein EWSR1::FLI1 Invades Nucleosomes at Consensus ETS Motifs and GGAA Microsatellites. bioRxiv : the preprint server for biology 56.0 27 Genomic Characterization of RTK-RAS Pathway Alterations in Juvenile Myelomonocytic Leukemia Through Whole-Exome Sequencing. Medical sciences (Basel, Switzerland) 65.9 28 Management of intractable emergence agitation with emotional and behavioural disinhibition in a child with anxiety requiring multiple anaesthetics. Anaesthesia reports 60.0 29 [Spitz tumors]. Pathologie (Heidelberg, Germany) 56.0 30 Pasireotide-LAR and pegvisomant combination in resistant acromegaly: a case series of predominantly mammosomatotroph adenomas. Pituitary 61.4 31 Successful Cytotoxic Chemotherapy-Free Bridging to Hematopoietic Stem Cell Transplantation With Dasatinib and Prednisolone/Blinatumomab for Relapsed Pediatric Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. Pediatric blood & cancer 55.06 32 Physical activity and exercise in pediatric oncology: conceptual distinctions and clinical implications. Turkish journal of physical medicine and rehabilitation 62.0
PATIENT-FRIENDLY SUMMARY

Educational and regional differences in population-based incidence and survival of primary central nervous system lymphoma in Finland.

For education only—not personal medical advice.

Before you continue

AI-assisted research information

Neurocompute uses AI to summarize scientific papers, interpret research signals, and suggest relevant reference links. AI-generated content can be incomplete, misleading, or wrong, and generated links may be irrelevant or unavailable.

Our reviewed outputs have performed strongly to date, but past accuracy is not a guarantee. Verify summaries, scores, claims, and links against the original publication before relying on them.

This platform is for research and education only. It does not provide medical advice, diagnosis, treatment recommendations, or clinical guidance.

Pediatric cancer research intelligence graphic
PEDIATRIC CANCER VISUAL SYSTEM

Open the Research Intelligence Map

Explore the active pediatric oncology analysis view.

Expand Intelligence View →
Full Pediatric cancer research intelligence graphic